Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: L773:0021 972X > Neurobehavioral def...

LIBRIS Formathandbok (Information om MARC21)

Details
MARC

Fältnamn	Indikatorer	Metadata
000		04947naa a2200385 4500
001		oai:DiVA.org:oru-83754
003		SwePub
008		200626s2015 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-837542 URI
024	7	a https://doi.org/10.1210/jc.2014-43232 DOI
040		a (SwePub)oru
041		a engb eng
042		9 SwePub
072	7	a ref2 swepub-contenttype
072	7	a art2 swepub-publicationtype
100	1	a Bellanger, Martineu EHESP School of Public Health, Paris, France4 aut
245	1 0	a Neurobehavioral deficits, diseases, and associated costs of exposure to endocrine-disrupting chemicals in the European Union
264	1	b Oxford University Press,c 2015
338		a print2 rdacarrier
500		a Funding Agency:Endocrine Society John Merck Fund Broad Reach Foundation Oak Foundation
520		a CONTEXT: Epidemiological studies and animal models demonstrate that endocrine-disrupting chemicals (EDCs) contribute to cognitive deficits and neurodevelopmental disabilities.OBJECTIVE: The objective was to estimate neurodevelopmental disability and associated costs that can be reasonably attributed to EDC exposure in the European Union.DESIGN: An expert panel applied a weight-of-evidence characterization adapted from the Intergovernmental Panel on Climate Change. Exposure-response relationships and reference levels were evaluated for relevant EDCs, and biomarker data were organized from peer-reviewed studies to represent European exposure and approximate burden of disease. Cost estimation as of 2010 utilized lifetime economic productivity estimates, lifetime cost estimates for autism spectrum disorder, and annual costs for attention-deficit hyperactivity disorder. Setting, Patients and Participants, and Intervention: Cost estimation was carried out from a societal perspective, ie, including direct costs (eg, treatment costs) and indirect costs such as productivity loss.RESULTS: The panel identified a 70-100% probability that polybrominated diphenyl ether and organophosphate exposures contribute to IQ loss in the European population. Polybrominated diphenyl ether exposures were associated with 873,000 (sensitivity analysis, 148,000 to 2.02 million) lost IQ points and 3290 (sensitivity analysis, 3290 to 8080) cases of intellectual disability, at costs of €9.59 billion (sensitivity analysis, €1.58 billion to €22.4 billion). Organophosphate exposures were associated with 13.0 million (sensitivity analysis, 4.24 million to 17.1 million) lost IQ points and 59 300 (sensitivity analysis, 16,500 to 84,400) cases of intellectual disability, at costs of €146 billion (sensitivity analysis, €46.8 billion to €194 billion). Autism spectrum disorder causation by multiple EDCs was assigned a 20-39% probability, with 316 (sensitivity analysis, 126-631) attributable cases at a cost of €199 million (sensitivity analysis, €79.7 million to €399 million). Attention-deficit hyperactivity disorder causation by multiple EDCs was assigned a 20-69% probability, with 19 300 to 31 200 attributable cases at a cost of €1.21 billion to €2.86 billion.CONCLUSIONS: EDC exposures in Europe contribute substantially to neurobehavioral deficits and disease, with a high probability of >€150 billion costs/year. These results emphasize the advantages of controlling EDC exposure.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Hälsovetenskapx Arbetsmedicin och miljömedicin0 (SwePub)303032 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Health Sciencesx Occupational Health and Environmental Health0 (SwePub)303032 hsv//eng
653		a Enviromental Science
653		a Miljövetenskap
700	1	a Demeneix, Barbarau Unité Mixte de Recherche, Muséum National d'Histoire Naturelle, Paris, France4 aut
700	1	a Grandjean, Philippeu Harvard School of Public Health, Boston, USA; University of Southern Denmark, Odense, Denmark4 aut
700	1	a Zoeller, R. Thomas,d 1952-u University of Massachusetts, Amherst, USA4 aut0 (Swepub:oru)tzr
700	1	a Trasande, Leonardou Department of Pediatrics, NYU, New York, USA; Wagner School of Public Service, New York, USA; Department of Nutrition, Food and Public Health, Steinhardt School of Culture, Education, and Human Development, New York, USA; Global Institute of Public Health, New York, USA4 aut
710	2	a EHESP School of Public Health, Paris, Franceb Unité Mixte de Recherche, Muséum National d'Histoire Naturelle, Paris, France4 org
773	0	t Journal of Clinical Endocrinology and Metabolismd : Oxford University Pressg 100:4, s. 1256-1266q 100:4<1256-1266x 0021-972Xx 1945-7197
856	4	u https://doi.org/10.1210/jc.2014-4323y Fulltext
856	4	u https://academic.oup.com/jcem/article-pdf/100/4/1256/17635847/jcem1256.pdf
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-83754
856	4 8	u https://doi.org/10.1210/jc.2014-4323

Find in a library

Journal of Clinical Endocrinology and Metabolism (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

By the author/editor: Bellanger, Marti ...; Demeneix, Barbar ...; Grandjean, Phili ...; Zoeller, R. Thom ...; Trasande, Leonar ...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Health Sciences; and Occupational Hea ...

Articles in the publication: Journal of Clini ...

By the university: Örebro University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se